(Q51393755)
Statements
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy (English)
H C Pitot
C Erlichman
R M Goldberg
J M Reid
J A Sloan
P A Skaff
J Rubin
P A Burch
S A Alberts
L J Schaaf
G Elfring